Detection and significance of PD-1.3 SNP (rs11568821) and IL28B SNP (rs12979860) in patients with current or past hepatitis B virus (HBV) infection Asterios Saitis 1 , Nikolaos K. Gatselis 1 , Kalliopi Azariadi 1 , Kalliopi Zachou 1 , George K. Koukoulis 2 , George N. Dalekos 1 1 Department of Medicine and Research Laboratory of Internal Medicine, School of Medicine, Thessaly University, Larissa, Greece 2 Department of Pathology, School of Medicine, Thessaly University, Larissa, Greece
24
Embed
Detection and significance of PD-1.3 SNP (rs11568821) and ... · Detection and significance of PD-1.3 SNP (rs11568821) and IL28B SNP (rs12979860) in patients with current or past
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Detection and significance of PD-1.3 SNP (rs11568821) and IL28B SNP (rs12979860) in patients with current or
past hepatitis B virus (HBV) infection
Asterios Saitis1, Nikolaos K. Gatselis1, Kalliopi Azariadi1, Kalliopi Zachou1, George K. Koukoulis2, George N. Dalekos1
1Department of Medicine and Research Laboratory of Internal Medicine, School of Medicine, Thessaly University, Larissa, Greece
2Department of Pathology, School of Medicine, Thessaly University, Larissa, Greece
Chronic Hepatitis C
Thomas et al, Nature 2009
Ge et al, Nature 2009
Response to Peg-IFN +RIBA Spontaneous HCV clearance
IL28B polymorphism (rs 12979860)
Chronic Hepatitis C
PD1.3 polymorphism (rs11568821)
Asociation analysis of PD-1 polymorphism with response to antiviral treatment
Genotypes SVR(n=210)
NR(n=197)
p value OR(95% CI)
PD-1.3 <0.05
G/G 150 (71.4%) 164 (83.2%)
G/A 50 (23.8%) 29 (14.7%)
A/A 10 (4.8%) 4 (2.1%)47.7
53.3
64.5
35.3
0
10
20
30
40
50
60
70
Response (n=210) Non-Response (n=197)
G/G
G/A or AA
Vidal-Castiñeira et al. Journal of Hepatology 2012
Chronic Hepatitis B
IL28B polymorphism PD1.3 polymorphism
Susceptibility to HBV infection?
Determinants of interferon response?
Chronic Hepatitis B
EASL Clinical Practice Guidelines, Journal of Hepatology 2017
Past infection95%
Chronic infection4-5%
Chronic hepatitis0.8-1%
Determinants
• Age of infection
• Genetic?• Genetic?
Chronic Hepatitis B
or
HBsAg clearance
48-week duration
High efficacy
High safety
Per os therapy
Inteferons Nucleoside/ Nucleotideanalogues
Genetic determinants of IFN response?
EASL Clinical Practice Guidelines, Journal of Hepatology 2017